Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the NHS supply of Futibatinib.

NHS England funds the use of licensed medicines that have been recommended by the National Institute for Health and Care Excellence (NICE). Futibatinib is licensed by the Medicines and Healthcare products Regulatory Agency and has been recommended by the NICE for the treatment of previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement. However, Taiho Pharma Europe, the company that markets futibatinib, has advised NHS England that they are not currently able to supply it to the National Health Service. Patients with previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement are able to access a different treatment, pemigatinib, which is also licensed and recommended by the NICE for this indication.